The FDA is calling for clinical trials to continue, with some precautions, into potential mortality risks linked to balloons and stents coated with paclitaxel.
The FDA is warning that paclitaxel-coated stents and balloons appear to significantly increase the risk of patients' deaths.
The FDA is conducting a safety review of paclitaxel-coated balloons and drug-eluting stents following a study suggesting they may increase the risk of death in recipients.
Use of the chemotherapy drug Taxol (paclitaxel) may significantly increase the risk of chronic neuropathic pain in breast cancer survivors, according to a new study from U.S. researchers.
